Recombinant Human Lactoferrin: An Opportunity to Treat the Neonatal and Adult Severe Sepsis
DOI:
https://doi.org/10.17140/EMOJ-9-168Keywords:
Severe sepsis, Preterm infants sepsis, Necrotizing enterocolitis, Sepsis preventionAbstract
Lactoferrin, both human and bovine, acts against oxidative stress damage and has a range of beneficial activities such as anti pathogenic, anti-cancer, anti-inflammatory, immunomodulatory, and deoxyribonucleic acid (DNA)-regulatory. In addition, clinical studies have shown human lactoferrin to attenuate inflammation and reduce mortality from neonatal and adult severe sepsis. However, the magnitude of the lactoferrin effect varies between studies. Given the demonstrated efficacy of recombinant human lactoferrin in sepsis, its lack of side effects, ease of administration, and relatively low cost, it is worth exploring whether the protein could be administered “preventively” as soon as the possibility of a patient’s condition progressing to severe sepsis is likely.
References
Kowalczyk P, Kaczyńska K, Kleczkowska P, Bukowska-Ośko I, Kramkowski K, Sulejczak D. The lactoferrin phenomenon-a miracle molecule. Molecules. 2022; 27(9): 2941. doi: 10.3390/mol-ecules27092941 Research Letter | Volume 9 | Number 1 |
Masson PL, Heremans JF. Lactoferrin in milk from different species. Comp Biochem Physiol. 1971; 39: 119-129. doi: 10.1016/0305- 0491(71)90258-6
Hennart PF, Brasseur DJ, Delogne-Desnoeck JB, Dramaix MM, Robyn CE. Lysoyzme, lactoferrin, and secretory immunoglobulin A content in breast milk: influence of duration of lactation, nutri-tion status, prolactin status, and parity of mother. Am J Clin Nutr. 1991; 53: 32-39. doi: 10.1093/ajcn/53.1.32
Hirai Y, Kawakata N, Satoh K, et al. Concentrations of lactofer-rin and iron at different stages of lactation. J Nutr Sci Vitaminol (Tokyo). 1990; 36: 531-544. doi: 10.3177/jnsv.36.531
Lupetti A, Paulusma-Annema A, Welling MM, et al. Synergistic activity of the N-terminal peptide of human lactoferrin and fluco-nazole against candida species. Antimicrob Agents Chemother. 2003; 47: 262-267. doi: 10.1128/AAC.47.1.262-267.2003
Manzoni P, Rinaldi M, Cattani S, et al. Bovine lactoferrin supple-mentation for prevention of late-onset sepsis in very low-birth-weight neonates. JAMA. 2009; 302: 1421-1428. doi: 10.1001/ jama.2009.1403
Picariello G, Ferranti P, Mamone G, Roepstorff P, Addeo F. Identification of N-linked glycoproteins in human milk by hydro-philic interaction liquid chromatography and mass spectrometry. Proteomics. 2008; 8(18): 3833-3847. doi: 10.1002/pmic.200701057
Hurley WL, Grieve RCJ, Magura CE, Hegarty HM, Zou S. Elec-trophoretic comparisons of lactoferrin from bovine mammary se-cretions, milk neutrophils, and human milk. J Dairy Sci. 1993; 76(2): 377-387. doi: 10.3168/jds.S0022-0302(93)77356-7
González-Chávez SA, Arévalo-Gallegos S, Rascón-Cruz Q. Lac-toferrin: Structure, function and applications. Int J Antimicrob Agents. 2009; 33(4): 301.e1-8. doi: 10.1016/j.ijantimicag.2008.07.020
Connely OM. Anti-inflammatory activities of lactoferrin. J Am Coll Nutr. 2001; 20(5 Suppl.): 389S-395S; discussion 396S-397S. doi: 10.1080/07315724.2001.10719173
Rodriguez DA, Vázquez L, Ramos G. Antimicrobial mecha-nisms and potential clinical application of lactoferrin. [In: Span-ish]. Rev Latinoam Microbiol. 2005; 47: 102-111.
Yamauchi K,Wakabayashi H, Shin K, Takase M. Bovine lacto-ferrin: benefits and mechanism of action against infections. Bio-chem Cell Biol. 2006; 84: 291-296. doi: 10.1139/o06-054
Drago SME. Enfermedades Infecciosas y Microbiología. [In: Spanish]. Enf Inf Microbiol. 2006; 26: 58-63.
Chapple DS, Hussain R, Joannou CL, et al. Structure and as-sociation of human lactoferrin peptides with escherichia coli lipo-polysaccharide. Antimicrobial Agents and Chemotherapy. 2004; 48(6): 2190-2198. doi: 10.1128/AAC.48.6.2190-2198.2004 Perspective | Volume 9 | Number 1 | Petrak K
Engelmayer J, Blezinger P, Varadhachary A. Talactoferrin stim-ulates wound healing with modulation of inflammation. J Surg Res. 2008; 149(2): 278-286. doi: 10.1016/j.jss.2007.12.754
Saarinen UM, Siimes MA. Iron absorption from infant milk formula and the optimal level of iron supplementation. Acta Pae-diatr Scand. 1977; 66: 719-722. doi: 10.1111/j.1651-2227.1977. tb07978.x
Siimes MA, Salmenperä L, Perheentupa J. Exclusive breastfeed-ing for 9 months: Risk of iron deficiency. J Pediatr. 1984; 104: 196- 199. doi: 10.1016/s0022-3476(84)80991-9
Caccavo D, Pellegrino NM, Altamura M, et al. Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. J Endotoxin Res. 2002; 8(6): 403-417. doi: 10.1179/096805102125001000
Puddu P, Valenti P, Gessani S. Immunomodulatory effects of lactoferrin on antigen presenting cells. Biochimie. 2009; 91(1): 11-8. doi: 10.1016/j.biochi.2008.05.005
Drago-Serrano ME, Campos-Rodríguez R, Carrero JC, de la Garza M. Lactoferrin: Balancing ups and downs of inflammation due to microbial infections. Int J Mol Sci. 2017; 18(3): 501. doi: 10.3390/ijms18030501
Edde L, Hipolito RB, Hwang FF, Headon DR, Shalwitz RA, Sherman MP. Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol Gastrointest Liver Physiol. 2001;2 81: G1140-G1150. doi: 10.1152/ajpgi.2001.281.5.G1140
Edde L, Conneely O, Headon D, Shalwitz RA, Sherman MP. Enteral lactoferrin mitigates gut-associated neonatal infection. Pe-diatr Res. 1999; 45: 45. doi: 10.1203/00006450-199904020-01158
Sherman MP, Bennett SH, Hwang FF, Yu C. Neonatal small bowel epithelia: Enhancing antibacterial defense with lactofer-rin and Lactobacillus GG. Biometals. 2004; 17(3): 285-289. doi: 10.1023/b:biom.0000027706.51112.62
Sherman MP, Miller MM, Sherman J, Niklas V. Lactoferrin and necrotizing enterocolitis. Curr Opin Pediatr. 2014; 26(2): 146-150. doi: 10.1097/MOP.0000000000000068
Sherman MP. Lactoferrin and necrotizing enterocolitis. Clin Perinatol. 2013; 40(1): 79-91. doi: 10.1016/j.clp.2012.12.006
Sherman MP, Pritzl CJ, Xia C, Miller MM, Zaghouani H, Hahm B. Lactoferrin acts as an adjuvant during influenza vaccination of neonatal mice. Biochem Biophys Res Commun. 2015; 467(4): 766-770. doi: 10.1016/j.bbrc.2015.10.067
Sherman MP, Adamkin DH, Niklas V, et al. Randomized con-trolled trial of talactoferrin oral solution in preterm infants. J Pedi-atr. 2016; 175: 68-73.e3. doi: 10.1016/j.jpeds.2016.04.084
U.S. National Institutes of Health (NIH), U.S. National Library of Medicine, clinicaltrials.gov. Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants. https://clinicaltrials. gov/ct2/show/NCT00854633. Accessed February 13, 2023.
Embleton ND, Berrington JE. Clinical trials of lactoferrin in the newborn: Effects on infection and the gut microbiome. Nestle Nutr Inst Workshop Ser. 2020; 94: 141-151. doi: 10.1159/000505334
Putting the Pieces Together HEALTH. Clinical Studies on Lactoferrin. https://www.ppt-health.com/clinical-studies-on-lac-toferrin/. Accessed February 13, 2023.
U.S. National Library of Medicine ClinicalTrials.gov. Recombi-nant Human Lactoferrin Administered Orally for the Prevention of Antibiotic-Associated Diarrhea in Adult Patients. ClinicalTri-als.gov Identifier: NCT01382199. https://clinicaltrials.gov/ct2/ show/NCT01382199. Posted June 27, 2011. Updated June 27, 2011. Accessed February 13, 2023.
Adis Insight. A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Recombinant Human Lactoferrin Administered Orally for the Prevention of Antibiotic Associated Diarrhea in Adult Patients. https://adisinsight.springer.com/trials/700245648. Updated No-vember 6, 2021. Accessed February 13, 2023.
Guntupalli K, Dean N, Morris PE, et al. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med. 2013; 41(3): 706-716. doi: 10.1097/CCM.0b013e3182741551
U.S. National Institutes of Health (NIH), U.S. National Li-brary of Medicine, clinicaltrials.gov. Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis. https:// clinicaltrials.gov/ct2/show/NCT00630656. Accessed February 13, 2023.
McCulloh R, Opal SM. Human recombinant lactoferrin for sepsis: Too good to be true? Crit Care Med. 2013; 41(3): 908-909. doi: 10.1097/CCM.0b013e3182770fd6
Vincent JL, Marshall JC, Dellinger RP, et al. Talactoferrin in se-vere sepsis: Results from the phase II/III Oral Talactoferrinin Se-vere Sepsis trial. Crit Care Med. 2015; 43: 1832-1838. doi: 10.1097/ CCM.0000000000001090
ProCESS Investigators; Yealy DM, Kellum JA, Huang DT, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014; 370(18): 1683-1693. doi: 10.1056/NEJ-Submit your article to this journal | https://openventio.org/submit-manuscript/ Moa1401602
Delaney AP, Peake SL, Bellomo R, et al. The Australasian Re-suscitation in Sepsis Evaluation (ARISE) trial statistical analysis plan. Crit Care Resusc. 2013; 15(3): 162-171.
Mouncey PR, Osborn TM, Power GS, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2015; 372: 1301-1311. doi: 10.1056/NEJMoa1500896
AGENNIX. Agennix AG halts Phase II/ III OASIS trial in se-vere sepsis. https://www.agennix.com/agennix-ag-halts-phase-ii-iii-oasis-trial-in-severe-sepsis/#:~:text=Planegg%2FMunich%20 %28Germany%29%2C%20February%202%2C%202012%20 %E2%80%93%20Agennix%20AG,II%2FIII%20OASIS%20 trial%20with%20talactoferrin%20in%20severe%20sepsis. Ac-cessed February 13, 2023.
Houston G, Cuthbertson BH. Activated protein C for the treat-ment of severe sepsis. Clin Microbiol Infect. 2009; 15(4): 319-324. doi: 10.1111/j.1469-0691.2009.02751.x
Rodriguez NA, Moya F, Landino J, et al. A randomized con-trolled trial of oropharyngeal therapy with mother’s own milk for premature infants [In: Online ahead of print]. J Perinatol. 2023. doi: 10.1038/s41372-022-01589-x
U.S. National Institutes of Health (NIH), U.S. National Library of Medicine, clinicaltrials.gov. Oropharyngeal Administration of Mother’s Colostrum for Premature Infants (NS-72393-360). https://clinicaltrials.gov/ct2/show/NCT02116699. Accessed February 13, 2023.
Patel B, Smith D, Siddiqui F. PROMISE, OASIS, and SWAT: Evaluating the future of sepsis care. Am J Respir Crit Care Med. 2016; 194(7): 907-908. doi: 10.1164/rccm.201604-0704RR
Huang DT, Angus DC, Barnato A, et al. Harmonizing inter-national trials of early goal-directed resuscitation for severe sepsis and septic shock: Methodology of ProCESS, ARISE, and ProM-ISe. Intensive Care Med. 2013; 39: 1760-1775. doi: 10.1007/s00134- 013-3024-7
Rivers E, Nguyen B, Havstad S, et al. Early goal-directed thera-py in the treatment ofsevere sepsis and septic shock. N Engl J Med. 2001; 345: 1368-1377. doi: 10.1056/NEJMoa010307
Hayden GE, Tuuri RE, Scott R, et al. Triage sepsis alert and sepsis protocol lower times to fluids and antibiotics in the ED. Am J Emerg Med. 2016; 34(1): 1-9. doi: 10.1016/j.ajem.2015.08.039 Research Letter | Volume 9 | Number 1 |
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Emergency Medicine (EM) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
